GRAL · GRAIL, Inc.
$132.55
+4.32% last session
End-of-day data · close of 2026-10-23
Market cap
$6B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-16.1
Dividend yield
0.0%
Beta
2.84
Avg volume
1M
Employees
1K
Daily Change %
4.32%
5 Days Change
7.85%
10 Days Change
-9.47%
30 Days Change
17.08%
60 Days Change
65.92%
Month to Day Change
-4.15%
Year to Day Change
48.45%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GRAL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-13
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$120
-9.5% vs priceUBS
Buy$175
+32.0% vs priceRBC Capital
Sector Perform$84.00
-36.6% vs priceGoldman Sachs
Neutral$60.00
-54.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Morgan Stanley | Maintains | Equal-Weight | $60.00 → $120 |
| 2026-10-13 | TD Cowen | Maintains | Buy | $88.00 → $180 |
| 2026-10-02 | UBS | Maintains | Buy | $105 → $175 |
| 2026-10-01 | Guggenheim | Maintains | Buy | $75.00 → $155 |
| 2026-09-28 | Canaccord Genuity | Maintains | Buy | $80.00 → $150 |
| 2026-09-25 | Mizuho | Maintains | Neutral | $65.00 → $100 |
| 2026-09-22 | Baird | Maintains | Outperform | $96.00 → $118 |
| 2026-09-17 | RBC Capital | Initiates | Sector Perform | $0.00 → $84.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 27.2% above the 50-day MA ($104.19).
- bullish: Price vs 200-day MA: Trading 72.5% above the 200-day MA ($76.86).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-2.84) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($43.03) and high ($154.08).
GRAL Price Chart
Loading chart for GRAL…
Fundamentals
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.